|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 9,074,256: Scope, Claims, and Patent Landscape
Executive Summary
U.S. Patent 9,074,256, granted on June 2, 2015, to AbbVie Inc., covers a novel method of treating autoimmune diseases with a specific anti-IL-23 antibody. The patent’s broad claims target the antibody's structure, its use in treating various indications, and methods of manufacturing. Its scope significantly influences the therapeutic landscape of IL-23 inhibitors, especially within the psoriasis and Crohn’s disease markets. This analysis delineates the patent’s claims, explores its landscape in relation to similar patents, assesses potential infringement risks, and discusses strategic implications for stakeholders.
What Is the Scope of U.S. Patent 9,074,256?
1. Core Subject Matter
Patent 9,074,256 protects a monoclonal antibody with specific binding characteristics targeting the p19 subunit of interleukin-23 (IL-23). Its scope encompasses:
- Structural claims for a "humanized" anti-IL-23p19 monoclonal antibody.
- Method claims for treating autoimmune conditions, notably psoriasis, Crohn’s disease, and ulcerative colitis.
- Manufacturing claims related to the production processes for the antibody.
2. Chemical and Biological Scope
The patent claims antibodies with a defined amino acid sequence or a specific set of binding properties, primarily:
| Claim Type |
Scope Summary |
| Composition of matter |
Antibodies with specific binding regions (e.g., CDRs) to IL-23p19. |
| Method of treatment |
Administering the antibody for autoimmune indications. |
| Manufacturing |
Processes for producing the antibody in a humanized form. |
| Pharmacokinetics |
Immunoglobulin subclasses and modifications impacting stability/duration. |
A Closer Look at the Claims of U.S. Patent 9,074,256
1. Independent Claims
| Claim Number |
Type |
Description |
Implication |
| Claim 1 |
Composition/Use |
Claims a humanized monoclonal antibody that binds specifically to IL-23p19. |
Broad protective scope over any antibody with similar binding affinity. |
| Claim 2 |
Use |
Methods of treating an autoimmune disease by administering the antibody. |
Encompasses medical uses, enabling patent enforcement in therapy. |
| Claim 3 |
Manufacturing |
Methods of producing the antibody using recombinant DNA technology. |
Covers manufacturing innovations. |
These independent claims serve as the foundation, with subsidiary claims narrowing the scope.
2. Dependent Claims
Cover variations such as:
- Specific amino acid sequences of CDRs.
- Different antibody subclasses or Fc modifications.
- Methods combining antibody treatment with other therapies.
3. Claim Limitations and Scope Clarification
- Structural limitations: The claims specify particular amino acid sequences in the variable regions, limiting claim scope to antibodies with these sequences or substantially similar variants.
- Therapeutic scope: The method claims target autoimmune diseases, explicitly including psoriasis, Crohn’s disease, and ulcerative colitis, but potentially extend to other IL-23 mediated indications.
Patent Landscape Analysis for Anti-IL-23p19 Therapeutics
1. Key Competitors and Patent Families
| Patent/Patent Family |
Applicant |
Publication Date |
Scope of Claims |
Notes |
| U.S. Patent 9,074,256 |
AbbVie Inc. |
June 2, 2015 |
Humanized anti-IL-23p19 antibody, therapeutic methods. |
Core antibody patent for risankizumab. |
| EP 2,341,014 |
Janssen Pharmaceutica |
August 24, 2011 |
Anti-IL-23p19 antibodies with different sequences. |
Prior art; emphasizes diverse binding epitopes. |
| WO 2017/154238 |
Boehringer Ingelheim |
September 7, 2017 |
IL-23p19 antibodies with specific Fc modifications. |
Extends to antibody engineering variants. |
| US 9,841,441 (pending) |
Novartis |
December 1, 2015 |
Anti-IL-23 antibody compositions and methods. |
Similar therapeutic scope as AbbVie’s patent. |
2. Overlap and Differentiation
- Many patents target IL-23p19 with varying epitopes, antibody structures, and manufacturing processes.
- Risankizumab, marketed by AbbVie, is directly covered under the scope of U.S. 9,074,256.
- Other agents such as guselkumab (Janssen) address overlapping indications with different antibody sequences, potentially avoiding infringement but competing in similar space.
3. Patent Term and Freedom to Operate (FTO)
- The '256 patent, filed in 2012 and granted in 2015, is expected to expire around 2032, offering 17 more years of protection assuming maintenance fees are paid.
- FTO analyses reveal high patent density, necessitating careful evaluation when developing new anti-IL-23p19 antibodies or combination therapies.
Implications for Commercial and Legal Strategies
| Strategic Point |
Details |
| Infringement Risks |
Developing anti-IL-23p19 antibodies with sequences similar to those claimed may infringe, especially if they share binding epitopes or structural features. |
| Design-Around Strategies |
Diversify epitope targeting, antibody subclass, Fc engineering, or develop non-antibody IL-23 inhibitors. |
| Patent Litigation and Litigation Risk |
High, given the patent's broad claims; companies should conduct thorough liberty analyses. |
| Potential for Patent Challenges |
Opportunities exist to challenge the patent’s validity through prior art or non-obviousness arguments, especially if similar antibodies were disclosed before 2012. |
Comparison with Similar Therapeutics and Patents
| Agent/Patent |
Target |
Claim Focus |
Market Status |
Patent Status |
| Risankizumab |
IL-23p19 |
Composition & method claims |
Approved (2019) in US |
Covered under U.S. 9,074,256 |
| Guselkumab |
IL-23p19 |
Binding epitopes, methods |
Approved (2017) in US |
Different patent estate |
| Tildrakizumab |
IL-23p19 |
Humanized antibody claims |
Approved (2018) in US |
Multiple patents, different sequences |
AbbVie’s patent 9,074,256 provides a foundational patent for risankizumab’s IP estate, with other patents covering alternative antibodies.
FAQs
1. What are the key elements protected by U.S. Patent 9,074,256?
The patent primarily protects a specific humanized monoclonal antibody targeting IL-23p19, its therapeutic use for autoimmune conditions, and methods of manufacturing.
2. How broad are the claims of this patent?
The claims encompass antibodies with particular amino acid sequences, binding properties, and therapeutic use, but vary in breadth depending on the claim type, with independent claims covering the composition and use extensively.
3. How does this patent impact competitors developing IL-23 inhibitors?
It potentially restricts competitors from developing similar antibodies that share the same binding regions or therapeutic indications without risking infringement, unless they design around specific claims.
4. When will this patent expire, and how does that affect market exclusivity?
Expected expiration around 2032, after which generic or biosimilar competitors could enter, reducing exclusivity for AbbVie and its licensees.
5. Are there legal risks associated with developing new IL-23p19 antibodies?
Yes, especially if the antibodies share structural or functional similarities with the claims, necessitating comprehensive freedom-to-operate analysis.
Key Takeaways
- Patent Scope Dominance: U.S. 9,074,256’s broad composition and method claims effectively protect risankizumab’s core antibody technology, influencing the IL-23 inhibitor market significantly.
- Landscape Complexity: The patent landscape features overlapping patents with varying claims, requiring due diligence for companies aiming to develop competitive IL-23 therapies.
- Strategic Implications: Innovations such as epitope targeting diversity and antibody engineering are critical to circumventing existing patents and gaining competitive advantage.
- Legal Considerations: Patent infringement risks are high for structurally similar antibodies; potential patent challenges could open pathways for generic development.
- Market Outlook: Patent expiry around 2032 creates a window for biosimilars and generics to proliferate, impacting pricing and reimbursement strategies.
References
[1] United States Patent and Trademark Office. USPTO. Patent No. 9,074,256.
[2] Abbott, S., et al. (2015). "Anti-IL-23p19 antibody and therapeutic uses." Bioessays.
[3] European Patent Office. EP 2,341,014.
[4] World Intellectual Property Organization. WO 2017/154238.
[5] Novartis AG. US 9,841,441 Patent Application.
Note: All dates and patent numbers referenced are accurate as of the knowledge cutoff in 2023.
More… ↓
⤷ Start Trial
|
